Cobimetinib in advanced melanoma with BRAF V600 mutation: Added benefit now considerable
Friday, June 3, 2016 - 13:30
in Health & Medicine
Further advantages of the drug Cobimetinib in comparison with the comparator therapy resulted from the analyses subsequently submitted by the drug manufacturer in the commenting procedure.